Lavipharm S.A. (ATH:LAVI)

Market Cap	162.45M
Revenue (ttm)	55.11M
Net Income (ttm)	3.27M
Shares Out	168.69M
EPS (ttm)	0.02
PE Ratio	78.83
Forward PE	n/a
Dividend	0.02 (2.08%)
Ex-Dividend Date	n/a

Volume	111,376
Average Volume	239,273
Open	0.9780
Previous Close	0.9630
Day's Range	0.9610 - 0.9790
52-Week Range	0.6500 - 1.0040
Beta	0.68
RSI	64.95
Earnings Date	Mar 26, 2026

About Lavipharm

Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, cosmetics, and healthcare products to physicians and pharmacists in Greece and internationally. The company offers pharmaceutical products for cardiology, oncology-urology, central nervous system, chronic pain, and self- treatment. It also provides prescription medicines and over the counter (OTC) products, as well as LIFELAB CBD products. The company was founded in 1911 and is based in Paiania, Greece.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1911
• Employees: 299
• Stock Exchange: Athens Stock Exchange
• Ticker Symbol: LAVI

Financial Performance

In 2024, Lavipharm's revenue was 52.95 million, an increase of 10.68% compared to the previous year's 47.84 million. Earnings were 8.98 million, an increase of 380.06%.